DSM, Crucell appoint Medarex VP as CEO of its newly formed PER.C6 R&D center

By Lisa Kerner

Charlotte, N.C., June 28 - Crucell NV and its technology partner, DSM Biologics BV, a business unit of Royal DSM NV, named Marco Cacciuttolo as chief executive officer of their newly created PER.C6 research and development center slated to open later this year in Cambridge, Mass.

Cacciuttolo was most recently a vice president at Medarex and was with previously with MedImmune, Inc.

The new R&D center will provide a fully integrated PER.C6 technology platform, including tailored cell culture media, fermentation processes, equipment design, scale-up, technology transfer and regulatory support.

Based in Leiden, the Netherlands, Crucell is a biotechnology company focused on vaccines and antibodies that prevent and treat infectious diseases.

DSM Biologics, located in the Netherlands, provides manufacturing technology and services to the biopharmaceutical industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.